Cargando…

Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展

Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849032/
https://www.ncbi.nlm.nih.gov/pubmed/33478191
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49
_version_ 1783645235440517120
collection PubMed
description Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of T cells, thus tumor immune escape. For example, depletion of peripheral effector T cell and accelerate the transformation of effector T cells into regulator T cells. To solve this problem, PD-1 antibody is used to bind to PD-1 on T cells to inhibit the interaction between PD-1 on the T cells and PD-L1 on the tumor cells so that it can restore the function of T cells to kill tumor cell. PD-1 antibodies, such as Nivolumab and Pembrolizumb, are approved as a first-line treatment for advanced non-small cell lung cell cancer. However, due to the interaction of tumor cells, T cells and cytokines, some patients developed drug resistance which reduces the efficacy of immunotherapy. Hence, how to overcome resistance has become a urgent problem. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex and the only known molecular receptor of immunoregulatory drugs, has been found to reverse PD-1 antibody resistance by binding to CRBN regulatory agents (CMS), exert T cell immune function by regulating proliferation, activation and metabolism of T cell. In this paper, the mechanism of down-regulation of T cells leading to resistance of PD-1 antibody in lung cancer, the mechanism of CRBN regulating T cells, and research progress of CRBN regulator in the treatment of lung cancer were reviewed.
format Online
Article
Text
id pubmed-7849032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-78490322021-02-04 Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 Zhongguo Fei Ai Za Zhi 综述 Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of T cells, thus tumor immune escape. For example, depletion of peripheral effector T cell and accelerate the transformation of effector T cells into regulator T cells. To solve this problem, PD-1 antibody is used to bind to PD-1 on T cells to inhibit the interaction between PD-1 on the T cells and PD-L1 on the tumor cells so that it can restore the function of T cells to kill tumor cell. PD-1 antibodies, such as Nivolumab and Pembrolizumb, are approved as a first-line treatment for advanced non-small cell lung cell cancer. However, due to the interaction of tumor cells, T cells and cytokines, some patients developed drug resistance which reduces the efficacy of immunotherapy. Hence, how to overcome resistance has become a urgent problem. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex and the only known molecular receptor of immunoregulatory drugs, has been found to reverse PD-1 antibody resistance by binding to CRBN regulatory agents (CMS), exert T cell immune function by regulating proliferation, activation and metabolism of T cell. In this paper, the mechanism of down-regulation of T cells leading to resistance of PD-1 antibody in lung cancer, the mechanism of CRBN regulating T cells, and research progress of CRBN regulator in the treatment of lung cancer were reviewed. 中国肺癌杂志编辑部 2021-01-20 /pmc/articles/PMC7849032/ /pubmed/33478191 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49 Text en 版权所有©《中国肺癌杂志》编辑部2021 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title_full Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title_fullStr Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title_full_unstemmed Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title_short Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
title_sort cereblon调节t细胞逆转pd-1抗体治疗肺癌耐药的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849032/
https://www.ncbi.nlm.nih.gov/pubmed/33478191
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49
work_keys_str_mv AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn
AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn
AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn